NASDAQ$PIII
P3 Health Partners Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced fourth quarter and full-year 2022 results, affirming 2023 guidance and introducing year-end medical margin guidance.
P3 Health Partners announced their Q4 2022 financial results, highlighting revenue growth and a network contribution improvement of 65% versus 2021. The company secured financing of approximately $90.0 million and anticipates reaching Adjusted EBITDA positive in early 2024.
- Achieved revenue growth in 2022.
- Improved network contribution by 65% versus 2021.
- Secured financing of approximately $90.0 million.
- Anticipates reaching Adjusted EBITDA positive in early 2024.
Headline financials
Revenue & EPS history
P3 Health · Revenue · Quarterly
$258M
Revenue by segment
P3 Health · $386M total across 2 segments · Q1 2026
- Capitated Revenue$379M—98.2%
- Other Revenue$6.89M—1.8%
Forward guidance
P3 Health Partners affirmed its 2023 guidance and expects to reach Adjusted EBITDA positive in early 2024, driven by a shift to a higher percentage of persistent lives, reduced operating expenses, and measured growth.
Tailwinds
- Shift to a higher percentage of persistent lives.
- Focused reduction in operating expenses.
- Measured and disciplined growth in 2023.
- Expectation to achieve Adjusted EBITDA profitability in 2024.
- Secured financing of approximately $90.0 million provides a solid path to profitability.
Headwinds
- Actual results may differ materially depending on a number of factors.
- Changes in market or industry conditions.
- Regulatory environment and competitive conditions.
- Impact of COVID-19, including the impact of new variants of the virus, or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation.
- Increased labor costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-3.8%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-15.6%
Avg return
30 days after
37%
7 / 19 earnings
Positive
+11.2%
Q1 2026
Best reaction
-36.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.2% | +194.4% | — | |
| Q4 2026 | +0.7% | -1.8% | -5.4% | |
| Q3 2025 | +0.4% | -12.6% | -25.9% | |
| Q2 2025 | -2.5% | +5.4% | +23.9% | |
| Q1 2025 | -0.6% | -5.9% | -19.5% | |
| Q4 2024 | -4.5% | +1.1% | -1.2% | |
| Q3 2024 | -36.8% | -42.2% | -46.0% | |
| Q2 2024 | -2.5% | -8.7% | -24.1% | |
| Q1 2024 | +2.6% | -11.8% | -21.6% | |
| Q4 2023 | -13.3% | -22.4% | -56.3% | |
| Q4 2021 | +3.1% | -7.6% | -12.2% | |
| Q3 2023 | -2.1% | -8.8% | -19.0% | |
| Q2 2023 | +0.9% | -10.8% | -5.0% | |
| Q4 2022 | -5.9% | -12.7% | +15.5% | |
| Q3 2022 | -11.8% | -19.7% | -33.5% | |
| Q1 2022 | -5.9% | +2.1% | -16.8% | |
| Q2 2022 | -4.1% | +0.6% | -14.0% | |
| Q3 2021 | +0.1% | +0.3% | -19.9% | |
| Q2 2021 | -0.7% | -0.2% | +0.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro